Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Plexxikon Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Plexxikon Inc. - Product Pipeline Review - 2015', provides an overview of the Plexxikon Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Plexxikon Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Plexxikon Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Plexxikon Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Plexxikon Inc.'s pipeline products Reasons to buy - Evaluate Plexxikon Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Plexxikon Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Plexxikon Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Plexxikon Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Plexxikon Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Plexxikon Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Plexxikon Inc. Snapshot 5 Plexxikon Inc. Overview 5 Key Information 5 Key Facts 5 Plexxikon Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Plexxikon Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Plexxikon Inc. - Pipeline Products Glance 13 Plexxikon Inc. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Plexxikon Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Plexxikon Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Plexxikon Inc. - Drug Profiles 17 PLX-3397 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PLX-8394 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PLX-9486 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PLX-7486 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules to Agonize PPAR for Multiple Sclerosis 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Plexxikon Inc. - Pipeline Analysis 25 Plexxikon Inc. - Pipeline Products by Target 25 Plexxikon Inc. - Pipeline Products by Route of Administration 26 Plexxikon Inc. - Pipeline Products by Molecule Type 27 Plexxikon Inc. - Pipeline Products by Mechanism of Action 28 Plexxikon Inc. - Recent Pipeline Updates 29 Plexxikon Inc. - Dormant Projects 31 Plexxikon Inc. - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 PLX-3397 32 PLX-3603 32 PLX-5622 32 Plexxikon Inc. - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Plexxikon Inc., Key Information 5 Plexxikon Inc., Key Facts 5 Plexxikon Inc. - Pipeline by Indication, 2015 7 Plexxikon Inc. - Pipeline by Stage of Development, 2015 9 Plexxikon Inc. - Monotherapy Products in Pipeline, 2015 10 Plexxikon Inc. - Out-Licensed Products in Pipeline, 2015 11 Plexxikon Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 12 Plexxikon Inc. - Phase III, 2015 13 Plexxikon Inc. - Phase II, 2015 14 Plexxikon Inc. - Phase I, 2015 15 Plexxikon Inc. - Preclinical, 2015 16 Plexxikon Inc. - Pipeline by Target, 2015 25 Plexxikon Inc. - Pipeline by Route of Administration, 2015 26 Plexxikon Inc. - Pipeline by Molecule Type, 2015 27 Plexxikon Inc. - Pipeline Products by Mechanism of Action, 2015 28 Plexxikon Inc. - Recent Pipeline Updates, 2015 29 Plexxikon Inc. - Dormant Developmental Projects,2015 31 Plexxikon Inc. - Discontinued Pipeline Products, 2015 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.